Browsing by Author Yoon, SK

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 10 of 10
TitleAuthor(s)Issue DateViews
 
Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease
Journal:Hepatology
Yuen, MFHan, KHUm, SHYoon, SKKim, HRKim, JKim, CRLai, CL
2010
128
 
Entecavir treatment for up to 5 years in patients with hepatitis b e antigen-positive chronic hepatitis B
Journal:Hepatology
Chang, TTLai, CLYoon, SKLee, SSCoelho, HSMCarrilho, FJPoordad, FHalota, WHorsmans, YTsai, NZhang, HTenney, DJTamez, RIloeje, U
2010
201
 
High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B
Journal:Clinical Gastroenterology and Hepatology
Pan, CQTong, MKowdley, KVHu, KChang, TLai, CYoon, SKLee, SSCohen, DTang, HTsai, N
2012
108
 
Interim report for a phase II, multi-centre, dose-escalating study of LB80380/ANA380 in hepatitis B patients with lamivudine-resistant YMDD mutant HBV
Proceeding/Conference:Journal of Hepatology
Lai, CLHan, KHYoon, SKUM, SHYuen, MFKim, HSKim, HRChung, HCKim, CRHsyu, PAverett, DKim, J
2005
89
 
Long-term entecavir treatment for up to 5 years in Asians with HBEAG-positive nucleos(T)ide naïve chronic hepatitis B: results from ETV-022 and -901
Proceeding/Conference:Hepatology
Pan, CTong, MJKowdley, KVHu, KQChang, TTLai, CLYoon, SKLee, SSCohen, DSTang, HTsai, N
2010
56
 
Phase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBV
Proceeding/Conference:Journal of Hepatology
Lai, CLHan, KHYoon, SKUm, SHYuen, MFKim, HSKim, HRChung, HCKim, CRHsyu, PAverett, DWorland, SKim, J
2006
152
 
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B
Journal:Gut
Lai, CLAhn, SHLee, KSUm, SHCho, MYoon, SKLee, JWPark, NHKweon, YOSohn, JHLee, JKim, JAHan, KHYuen, RMF
2013
135
 
A phase IIb study of the efficacy and safety of LB80380 vs entecavir in treatment-naive patients with chronic hepatitis B
Proceeding/Conference:Hepatology
Lai, CLAhn, SHLee, KSUm, SHCho, MYoon, SKLee, JWPark, NWKwon, YOSohn, JHLee, JYPark, HEKim, JAHan, KHYuen, MF
2011
60
 
Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: Results from a multicentre study
Journal:Journal of Hepatology
Yuen, RMFAhn, SHLee, KSUm, SHCho, MYoon, SKLee, JWPark, NHKweon, YOSohn, JHLee, JKim, JALai, CLHan, KH
2015
66
 
Week 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B
Proceeding/Conference:Hepatology
Lai, CLAhh, SHLee, KSUm, SHCho, MYoon, SKLee, JWPark, NHKweon, YOSohn, JHLee, JKim, JAHan, KHYuen, MF
2011
59
Showing results 1 to 10 of 10